The NYSE Welcomes vVARDIS as a Publicly Listed Company

• vVARDIS debuted on the NYSE, offering a drill-free, needle-free treatment for early tooth decay. • Curodont Repair Fluoride Plus uses peptide technology to remineralize enamel, avoiding fillings. • The treatment has been used on 2.5 million+ teeth, available in over 20% of U.S. dental practices. vVARDIS (NYSE: VVVV), a Swiss dental technology company co-founded by Dr. Haley Abivardi and Dr. Goly Abivardi, is now publicly listed on the NYSE. The company aims to change how early tooth decay is treated, targeting a condition that affects billions worldwide while dental anxiety keeps many from seeking care. Its flagship product, Curodont Repair Fluoride Plus, uses proprietary peptide technology to repair early-stage tooth decay by supporting natural enamel remineralization — without drills, needles, or fillings. Tooth decay remains one of the most widespread health issues globally: 2.5 billion people live with untreated decay, nearly 90% of U.S. adults have experienced it, and about 73% report dental fear, with 21% avoiding the dentist due to anxiety. The founders spent 25 years developing Curodont, which has now been used to treat more than 2.5 million teeth and is available in over 20% of U.S. dental practices, giving dentists a less intimidating way to address decay before it becomes a cavity.